Senses Disorder TRIZ Cases

Novel aniline-based TLX modulators simplify scaffold design while improving target engagement, potency, and selectivity for TLX insufficiency.

A defined IGF1 and STAT3 activator medium enables direct iPS-to-corneal endothelium differentiation without animal-derived components.

Intraocular delivery of multiple proneural bHLH factors reprograms Müller glia without retinal injury or added agents, boosting retinal neuron output.

An oral magnesium and vitamin antioxidant formulation restores hearing by scavenging cochlear free radicals and promoting vasodilation.

Peptide fragments modulate intracellular signaling to curb inflammatory mediator release in uveitis while avoiding steroid-like side effects.

N-acylated fatty amino acid carriers and absorption enhancers improve oral uptake of plant compounds, boosting bioavailability and onset.

Selective picrotoxane-type sesquiterpenes from Dendrobii Caulis protect retinal and optic nerve cells while avoiding the cytotoxicity of other extract components.

Opioid enantiomers modulate CFTR and inhibit basophil degranulation to restore tear secretion and reduce ocular inflammation.

AAV8 delivery with an M-opsin promoter and optimized CNGA3 expression restores cone function and prolongs cone survival in retinal disorders.

A stable polymorph B of 6-fluoro-9-methyl-β-carboline improves formulation consistency, bioavailability, and storage stability.

Targeting FAM19A5 with an antibody reduces glaucoma-related inflammation and preserves retinal ganglion cells, including in normal-tension glaucoma.

Polymer-conjugated anti-CFD antibodies extend ocular residence time, reducing dosing frequency for dry AMD and geographic atrophy treatment.

AAV delivery enables RPE cells to sustain anti-VEGF expression, reducing repeat eye injections, side effects, and systemic blood exposure.

A dual-acting valsartan-NEPi co-crystal combines ARB and neprilysin inhibition in one compound to improve blood pressure control with fewer dosing issues.

NACA improves retinal penetration over NAC to raise glutathione, reduce cone cell death, and slow retinitis pigmentosa progression.

Hydrogen or H2:O2 eye formulations reduce inflammation and VEGF while avoiding steroid-linked cataracts and elevated eye pressure.

Histidine buffer replaces citrate to prevent anti-TRBV9 antibody aggregation and preserve long-term stability and biological activity.

Short C-terminal Serpin peptides retain immune-modulatory activity while reducing protein treatment complexity and cost for inflammatory disease therapy.

A non-aqueous alkylammonium EDTA salt chelates metal ions in lipid formulations to limit oxidation and preserve active-agent stability.

Targeted amino acid substitutions near Hyal1 catalytic residues enable hyaluronic acid hydrolysis from acidic to neutral pH for drug delivery use.

A vitreous-matched semifluorinated alkane tamponade helps treat retinal detachment while limiting refractive mismatch and emulsification.

Decellularized Descemet's membrane replaces amniotic membrane to expand limbal stem cells while preserving phenotype and lowering rejection risk.

A bispecific antibody binds CFHR4 and C3 to modulate complement activity and address both wet AMD and geographic atrophy.

Fc and variable region amino acid changes extend anti-IL-6 receptor antibody half-life while lowering immunogenicity and stability risks.

Small-molecule OCT4 promoter activators replace viral vectors to improve stem cell reprogramming safety while reducing GMP complexity and cost.

A vitreous-matched semifluorinated alkane and oil mixture improves retinal tamponade while reducing refractive mismatch and emulsification.

Specific SHP2 inhibitor structures improve selectivity, bioavailability, and brain penetration for treating SHP2-related diseases.

Topical levodopa with an antioxidant raises intraocular dopamine to inhibit myopia progression while avoiding systemic dopamine elevation.

Systemic monomeric Annexin A5 targets retinal occlusions to modulate the blood-retinal barrier and reduce edema without intravitreal injections.

Novel pendrin corrector compounds promote proper folding, membrane localization, and ion transport to address pendred syndrome defects.

Engineered Fc immunoglobulins coengage FcγRIIb and CD19 to curb B cell activation and reduce IgG4-related disease symptoms.

Cell-specific inner ear promoters in AAV constructs boost connexin 26 expression in support cells to address GJB2-related hearing loss.

Codon-optimized CNGA3, CNGB3, and REP-1 sequences in rAAV vectors improve retinal protein expression and functional recovery for ocular disorders.

A defined truncation variant limit of 20% helps preserve aflibercept binding activity while avoiding extra removal steps.

See how OCT identifies retinal organoid regions at least 70 µm thick and free of foreign structures for uniform transplant sheets.

Ammonia-oxidizing microorganisms convert nasal ammonia to nitrite, helping restore the microbiome and reduce congestion and inflammation.

Low- or neutral-pI antibodies can aggregate at commercial concentrations; ionic excipients improve colloidal stability in the 5.5–6.5 pH range.

Engineered HCAb sequences target PDGF and related growth factors to inhibit pathological angiogenesis in retinal disease.

A p62 ligand and target-binding ligand deliver protein aggregates to autophagosomes for lysosomal degradation.

Controlled peripheral blurring in therapeutic glasses reduces retinal image spatial frequency to help limit further eye lengthening.

α-2,6-sialylated immunoglobulin induces DC-SIGN-mediated tolerance and IL-10 expression to address dry eye inflammation without corneal fibrosis.

A heterologous peptide inserted into the AAV capsid GH loop improves retinal-layer localization and infectivity for gene delivery.

Amide-substituted aromatic derivatives selectively target TYK2 to address efficacy and safety trade-offs linked to broad JAK inhibition.

This compound inhibits Lp-PLA2 to address inflammatory and oxidative stress mechanisms in Alzheimer’s disease, glaucoma, AMD, and atherosclerosis.

MCOs restore retinal light sensitivity at low intensities by expressing synthetic opsins in retinal cells after photoreceptor degeneration.

Modified compstatin analogs use tailored dosing regimens, formulations, and routes to maintain complement inhibition across selected disorders.

Surfactant-free selenium disulfide stays uniformly dispersed in an anhydrous semi-solid base to limit aggregation and ocular surface interactions.

Antibodies targeting FAM19A5 inhibit retinal angiogenesis, improve retinal potentials, and reduce vascular congestion.

Nanomolar PARP-1 inhibition and cytoprotection position isoquinolinone derivatives for earlier intervention in retinal disorders.